What type of study is this?

This is a Pilot Study study (also classified as: Observational).

Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia

View Full Paper

Ask AI

Bookmark

Authors

Pilot study identifies immune markers associated with infection risk in relapsed chronic lymphocytic leukaemia, suggesting new predictive approaches.

Forty-six percent of patients developed an infection during nine months of monitoring, indicating a significant risk.
Infection risk was linked with an inflammatory transcriptome profile at three months post-ibrutinib treatment, highlighting immune interactions.
Analysis of PBMCs using Luminex and RNA sequencing revealed potential immune signatures for future validation in large cohorts.
Increased protein response to PMA at three and six months was connected to a higher likelihood of developing infections, marking a key finding.

Williams et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Pilot study identifies immune markers associated with infection risk in relapsed chronic lymphocytic leukaemia, suggesting new predictive approaches.